Cardiometabolic benefits of glucagon-like peptide-1 receptor agonists and dual agonists: from obesity and diabetes to heart failure with preserved ejection fraction.
Abstract
INTRODUCTION Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalisations and is increasing in prevalence, largely driven by obesity and Type 2 Diabetes Mellitus (T2DM). Glucagon-like-peptide receptor agonists (GLP-1 RAs) and the dual GLP-1/GIP agonist, tirzepatide, have been shown to be safe and effective medications in the treatment of T2DM and obesity as well as in obesity-related HFpEF. AREAS COVERED This review summarises the pathophysiology of obesity-related HFpEF, mechanisms by which GLP-1 RAs and tirzepatide may improve symptoms and outcomes, and summarise evidence from recent randomised controlled and observational trials across the disease spectrum they have been studied in. Therapeutic implications and future research directions are also discussed. A structured literature search was performed using PubMed/MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) up to August 2025. EXPERT OPINION GLP-1 receptor agonists and tirzepatide represent a promising therapeutic advance for obesity-related HFpEF. Benefits are likely mediated through weight loss dependent and weight-loss independent mechanisms. Important uncertainties remain regarding their role in non-obese HFpEF, optimal patient selection, and their safety in HFrEF.